A Study of the Interaction Between BCG And MenC Immunisation: BAM

NCT ID: NCT02002156

Last Updated: 2018-10-18

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE4
• Total Enrollment: 28 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-06-20
• Study Completion Date: 2018-06-27

Brief Summary

The Bacille Calmette-Guérin (BCG) vaccine is the only vaccine licenced to prevent tuberculosis (TB). The stimulus it gives to the immune system allows it to respond more effectively to a subsequent infection with TB.

Many studies have shown that BCG is effective in reducing deaths from TB disease, particularly in children. However, there is also evidence that in countries with a relatively high death rate, BCG reduces this death rate but by more than would be expected by its effect on TB alone. This controversial but important finding warrants further and serious consideration. One possibility is that BCG, in addition to stimulating the immune system against TB, also has a positive effect on the way the immune system works more generally. This might mean a more effective response to serious infections that are completely unrelated to TB, or the ability to respond better to other routine childhood vaccines, or to maintain such responses for longer. In these examples, the timing of BCG administration in relation to other vaccines could be crucial.

This study will recruit 30 healthy babies who would not routinely be offered the BCG vaccine in the UK within the first week of life. Babies will be assigned at random to one of three groups of ten babies each. BCG will be given to one group of babies around birth, one at three months old and the last group will not get BCG during the study. Babies will stay in the study until 13 months old and have five blood tests over this period.

This preliminary study will look at the participants' blood to see if there are differences in the immune system, or its response to the MenC childhood meningitis vaccine or the pattern of genes activated after BCG has been given.

Conditions

BCG Infection; Reaction - Vaccine; Immune Response

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: NONE

Study Groups

BCG at birth and routine vaccines

BCG, NeisVac-C®, Pediacel®, Infanrix™, Prevenar-13®, Menitorix®, Priorix®, Rotarix®

Group Type: EXPERIMENTAL

BCG, NeisVac-C®, Pediacel®, Infanrix™, Prevenar-13®, Menitorix®, Priorix®, Rotarix®

Intervention Type: BIOLOGICAL

This group will receive BCG at birth and all routine vaccinations.

BCG at 3 months old and routine vaccines

BCG, NeisVac-C®, Pediacel®, Infanrix™, Prevenar-13®, Menitorix®, Priorix®, Rotarix®

Group Type: EXPERIMENTAL

BCG, NeisVac-C®, Pediacel®, Infanrix™, Prevenar-13®, Menitorix®, Priorix®, Rotarix®

Intervention Type: BIOLOGICAL

This group will receive BCG at three months old and all routine vaccinations.

Routine vaccines

NeisVac-C®, Pediacel®, Infanrix™, Prevenar-13®, Menitorix®, Priorix®, Rotarix®

Group Type: EXPERIMENTAL

NeisVac-C®, Pediacel®, Infanrix™, Prevenar-13®, Menitorix®, Priorix®, Rotarix®

Intervention Type: BIOLOGICAL

This group will receive no BCG but will receive all routine vaccinations.

Interventions

BCG, NeisVac-C®, Pediacel®, Infanrix™, Prevenar-13®, Menitorix®, Priorix®, Rotarix®

This group will receive BCG at birth and all routine vaccinations.

Intervention Type: BIOLOGICAL

BCG, NeisVac-C®, Pediacel®, Infanrix™, Prevenar-13®, Menitorix®, Priorix®, Rotarix®

This group will receive BCG at three months old and all routine vaccinations.

Intervention Type: BIOLOGICAL

NeisVac-C®, Pediacel®, Infanrix™, Prevenar-13®, Menitorix®, Priorix®, Rotarix®

This group will receive no BCG but will receive all routine vaccinations.

Intervention Type: BIOLOGICAL

Other Intervention Names

BCG vaccine (Serum Statens Institute); NeisVac---C®, Baxter Healthcare Ltd.; Pediacel®, Sanofi Pasteur MSD Ltd.; Infanrix™---IPV---Hib, GlaxoSmithKline; Prevenar---13®, Pfizer Ltd.; Menitorix®, GlaxoSmithKline UK; Priorix®, GlaxoSmithKline UK; Rotarix®, GlaxoSmithKline UK; BCG vaccine (Serum Statens Institute); NeisVac---C®, Baxter Healthcare Ltd.; Pediacel®, Sanofi Pasteur MSD Ltd.; Infanrix™---IPV---Hib, GlaxoSmithKline; Prevenar---13®, Pfizer Ltd.; Menitorix®, GlaxoSmithKline UK; Priorix®, GlaxoSmithKline UK; Rotarix®, GlaxoSmithKline UK; NeisVac---C®, Baxter Healthcare Ltd.; Pediacel®, Sanofi Pasteur MSD Ltd.; Infanrix™---IPV---Hib, GlaxoSmithKline; Prevenar---13®, Pfizer Ltd.; Menitorix®, GlaxoSmithKline UK; Priorix®, GlaxoSmithKline UK; Rotarix®, GlaxoSmithKline UK

Eligibility Criteria

Inclusion Criteria

Healthy male or female babies aged 7 days or under

• Born at term (≥ 36 completed weeks of gestation)
• Valid informed consent provided by an individual with parental responsibility (parent or legal guardian)
• Living within the Thames Valley region at enrolment without intention to move out of this region during the course of the study
• Parents or legal guardians must be aged 18 years or over
• Parent or legal guardian is able (in the Investigator's opinion) and willing to comply with all study requirements
• Parent or legal guardian consent provided for General Practitioner and consultant, if appropriate, to be notified of participation in the study
• Parent or legal guardian consent to review hospital birth records before enrolment and inform GP or Consultant of involvement in study, if appropriate

Exclusion Criteria

Confirmed, suspected or significant risk of immunodeficiency (including but not limited to: maternal history of Human Immunodeficiency Virus infection, family history of congenital or hereditary immunodeficiency and receipt of significant immunosuppressive medication by the participant during the study, or by the mother prior to delivery)

• Receipt of BCG or another live vaccine prior to enrolment
• Receipt of any vaccine, either prior to enrolment or planned during the study, except for:

• those listed in the study protocol at the times indicated
• hepatitis A or B vaccine or influenza vaccine.
• Receipt prior to enrolment, or planned receipt during the study, of monoclonal antibodies, immunoglobulin or any blood product
• A baby who would normally be offered BCG at birth under current Department of Health guidance3. This means:

• babies living in an area of the UK with an annual incidence of TB >40 / 100,000 or
• babies who have a parent or grandparent who was born in a country with an annual incidence of TB >40 / 100,000
• Confirmed or suspected household contact with active TB
• Confirmed or suspected anaphylaxis to any component of BCG or other study vaccine
• Any confirmed or suspected serious medical condition (including seizures, neurological conditions, major congenital abnormalities or malignancy)
• Receipt of systemic antimicrobial medication since birth
• Parents or legal guardians should not be members of the study team or named on the study delegation log
• Any other significant disease or disorder which, in the opinion of the Investigator, may either put the potential participant (or carer) at risk because of participation in the study, or may influence the result of the study, or the potential participant's ability to participate in the study.
• A potential participant who has participated or is participating in another research study involving an investigational product

• Maximum Eligible Age: 7 Days
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

University of Oxford

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

University of Oxford, Oxford Vaccine Group

Oxford, Oxfordshire, United Kingdom

Countries

United Kingdom

Other Identifiers

OVG-2013/04

Identifier Type: -

Identifier Source: org_study_id